Connor, Clark & Lunn Investment Management Ltd. Amylyx Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $26 Billion
- Q2 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 1,154,485 shares of AMLX stock, worth $17.7 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,154,485
Previous 1,199,691
3.77%
Holding current value
$17.7 Million
Previous $4.25 Million
74.28%
% of portfolio
0.03%
Previous 0.02%
Shares
8 transactions
Others Institutions Holding AMLX
# of Institutions
145Shares Held
75.8MCall Options Held
212KPut Options Held
40.6K-
Adage Capital Partners Gp, L.L.C. Boston, MA8.8MShares$135 Million0.1% of portfolio
-
Perceptive Advisors LLC New York, NY7.9MShares$121 Million2.22% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.94MShares$90.9 Million7.77% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.54MShares$69.4 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$68.8 Million0.0% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $895M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...